XKRX
290650
Market cap1.03bUSD
Oct 08, Last price
56,400.00KRW
1D
-3.26%
1Q
-22.42%
IPO
517.52%
Name
L&C Bio Co Ltd
Chart & performance
P/E
—
P/S
16.24
EPS
—
Div yield, %
0.09%
Shrs. gr., 5y
2.37%
Rev. gr., 5y
20.99%
Revenues
85.48b
+18.56%
Net income
-138.17b
L
CFO
12.56b
P
Dividend
Dec 29, 202550 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Specializing in regenerative tissue medicine, L&C BIO Co., Ltd. operates as a dedicated research and development enterprise. The company's diverse product range encompasses human tissue products, various medical devices, and a selection of cosmetic solutions. Established in 2011, this firm is headquartered in Seongnam, South Korea.
Key people
Jae Ho Lee
Co-Chief Executive Officer, Chief Financial Officer, Director · since 2025
Hak Gyu Bae
Vice President
Vice President
Gi Min Kim
Assistant Managing Director
Gwang Yin Lee
Assistant Managing Director
Su Seong Yim
Assistant Managing Director
Hyeong Gu Kim
Vice President, Director
Co-Chief Executive Officer, Director · since 2025
Ruiheng Zhang
Other Non-Executive Director
Tae Seon Jeon
Non-Executive Independent Director · since 2023
Seong Jong Park
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||